HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 374 participants.

Also called NCT03550859

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 374 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03550859
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03550859. Randomized; no masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
Condition
Proteinuria
Intervention (Drug)
Telmisartan/Rosuvastatin 40/10mg
Intervention (Drug)
Telmisartan 40mg
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct03550859
Content hash
5fc8f701fcb01792cf720788b5e15ca9fa45306a0245db1e0d0335b0462d849e